Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 9:28 AM ET

Company Overview of The Multiple Myeloma Research Foundation, Inc

Company Overview

,  

United States

Founded in 1998

Key Executives for The Multiple Myeloma Research Foundation, Inc

Chief Executive Officer, President and Chief Operating Officer
Age: 49
Founder and Executive Chairman
Age: 55
Founder
Age: 59
Vice President of Communications
Chief Development and Marketing Officer
Compensation as of Fiscal Year 2014.

The Multiple Myeloma Research Foundation, Inc Key Developments

Multiple Myeloma Research Foundation, University of Torino and Adaptive Biotechnologies Work to Speed Novel Minimal Residual Disease Monitoring Technologies to Patients

The Multiple Myeloma Research Foundation (MMRF), in collaboration with the University of Torino (UofT) and Adaptive Biotechnologies, announced a collaboration to perform sequencing-based assessment of minimal residual disease (MRD) on hundreds of multiple myeloma (MM) patients over a five year period. The purpose of this initiative is to investigate a new approach to monitoring MRD. This collaboration, partially supported by Amgen, will be part of the INSIDE MM-1 study, led by Professor Antonio Palumbo from UofT. Professor Palumbo presented promising results of an earlier study at the 2013 American Society for Clinical Oncology (ASCO) annual meeting. This earlier study, funded by a 2010 Diagnostics Investment Award from the MMRF, set the stage for INSIDE MM-1, a groundbreaking, comparative, clinical disease monitoring trial. More than 400 newly diagnosed MM patients will be enrolled in INSIDE MM-1 and will receive a combination of carfilzomib and lenalidomide, followed by a bone marrow transplant with or without maintenance. Patients will be monitored for MRD using both flow cytometry and Adaptive Biotechnologies’ clonoSEQ MRD test at regular intervals from initial diagnosis for up to five years after initial treatment.

The Multiple Myeloma Research Foundation Appoints Wynton Marsalis to Honorary Board of Directors

The Multiple Myeloma Research Foundation (MMRF) announced that Managing and Artistic Director of Jazz at Lincoln Center, Wynton Marsalis has joined the MMRF Honorary Board.

The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM

The Multiple Myeloma Research Foundation, Inc Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 04:00 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Daniel Auclair, Vice President, Translational Research.

Similar Private Companies By Industry

Company Name Region
Sherwood Escrow, Inc. United States
Echols Oil Company United States
UNICO Bank United States
Harlan & Associates United States
ServiceNet, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Multiple Myeloma Research Foundation, Inc, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.